Stereochemistry | ACHIRAL |
Molecular Formula | C16H24N4O3 |
Molecular Weight | 320.3868 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCN1C2=C(N(CC(C)=O)C=N2)C(=O)N(CCCC)C1=O
InChI
InChIKey=HJPRDDKCXVCFOH-UHFFFAOYSA-N
InChI=1S/C16H24N4O3/c1-4-6-8-19-14-13(18(11-17-14)10-12(3)21)15(22)20(16(19)23)9-7-5-2/h11H,4-10H2,1-3H3
Denbufylline is a selective xanthine derivative that inhibits PDE IV and has bronchodilatory properties. Shown to exhibit negative inotropic effects by acting on verapamil-sensitive sites of Ca2+ channels in guinea pig ventricle papillary muscle independently of its PDE inhibitory activity. Denbufylline, a selective type 4 phosphodiesterase (PDE-4) inhibitor, is a potent activator of the hypothalamo-pituitary-adrenal (HPA) axis when given orally or intraperitoneally (i.p.) to adult male rats. Denbufylline was being developed as an agent for the therapy of dementia.
CNS Activity
Originator
Approval Year
Doses
Sourcing
PubMed
Patents
Sample Use Guides
The patients with dementia of the Alzheimer type (DAT) were randomly allocated to denbufylline 25, 50 or 100 mg or to placebo given twice daily for 16 weeks.
Route of Administration:
Oral